GPM Reminds Investors of the October 31st Deadline in the Class Action Lawsuit Against American Renal Associates Holdings, In...
October 21 2016 - 10:30AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the
October 21, 2016 deadline to file a lead plaintiff motion in
the class action lawsuit filed on behalf of investors who purchased
or otherwise acquired American Renal Associates Holdings, Inc.
(“American Renal” or the “Company”) (NYSE: ARA) securities: (1)
pursuant and/or traceable to American Renal’s false and misleading
Registration Statement and Prospectus issued in connection with the
Company’s initial public offering on or around April 21, 2016 (the
“IPO” or the “Offering”); and/or (2) on the open market between
April 21, 2016 and August 18, 2016, both dates inclusive (the
“Class Period”).
The Complaint alleges that throughout the Class Period,
Defendants made false and/or misleading statements or failed to
disclose that: (i) American Renal was engaged in a fraudulent
scheme to steer patients away from qualified-for Medicare and
Medicaid plans into more expensive Affordable Care Act (“ACA”)
plans to obtain greater reimbursement for the Company’s dialysis
services; (ii) the foregoing scheme was in violation of federal and
state laws; and (iii) as a result of the foregoing, American
Renal’s public statements were materially false and misleading at
all relevant times.
If you purchased or otherwise acquired American Renal shares
during the Class Period, you may move the Court no later
than October 31, 2016 to request appointment as
lead plaintiff. To be a member of the class you need not take any
action at this time; you may retain counsel of your choice or take
no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161021005123/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
American Renal Associates (NYSE:ARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
American Renal Associates (NYSE:ARA)
Historical Stock Chart
From Apr 2023 to Apr 2024